Durvalumab
Brand: Imfinzi (global) / Durvalumab (IN/BD)
Anticancer
PD-L1 Immune Checkpoint Inhibitor
Pharmacokinetics
| Half-life | 432 hours |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Fixed dose 1500 mg IV every 4 weeks (q28). RAW70 historical dosing was 10 mg/kg. |
⚠️ Safety & Warnings
Severity: Life-threatening
Adverse Effects:
Immune pneumonitis, hepatitis, colitis, endocrinopathy
Contraindications:
Severe active autoimmune disease
Precautions:
Baseline TSH, cortisol, AST/ALT; treat grade ≥3 toxicities with steroids
INSERT PK
half-life ~18 days → 18×24 = 432 hours
Current standard dose: 1500 mg every 4 weeks.